Skip to main navigation Skip to search Skip to main content

Polymeric antigen BLSOmp31 formulated with class B CpG-ODN in a nanostructure (BLSOmp31/CpG-ODN/Coa-ASC16) administered by parenteral or mucosal routes confers protection against Brucella ovis in Balb/c mice

  • Maria Celeste Moran
  • , Angel Ricardo Bence
  • , Maria Fernanda Sanchez Vallecillo
  • , Claudia Maria Lutzelschwab
  • , Marcelo Gaston Rodriguez
  • , Romina Pardo
  • , Fernando Alberto Goldbaum
  • , Vanesa Zylberman
  • , Santiago Daniel Palma
  • , Belkys Angelica Maletto
  • , Silvia Marcela Estein
  • , et al.

    Publication: Contribution to journal › Journal article › peer-review

    Abstract

    Previously, we demonstrated that the chimera BLSOmp31 formulated in chitosan microspheres or Poloxamer407-Chitosan administered via the nasal and the ocular mucosa conferred partial protection in sheep against B. ovis. In this work, we tested a new delivery system for mucosal immunization with BLSOmp31 in the murine model to improve the efficacy of previously used formulations. First, we evaluated the protective efficacy against B. ovis induced by BLSOmp31 administered by the subcutaneous route using either BLSOmp31 alone, coadministered with immunostimulatory synthetic oligodeoxynucleotides containing unmethylated cytosineguanine motifs (CpG-ODN) or with CpG-ODN in a nanostructure called Coa-ASC16 compared with BLSOmp31 emulsified in Incomplete Freund Adjuvant. Then, we evaluated the protection conferred by the best performing formulation (BLSOmp31/CpG-ODN/Coa-ASC16) administered by both subcutaneous and ocular routes. BLSOmp31/CpG-ODN/Coa-ASC16 injected subcutaneously did not induce higher IgG antibody levels compared to BLSOmp31 alone or BLSOmp31/CpG-ODN but it did stimulate a mixed immune Th1-Th2 response with the highest levels of IFN-? and conferred significant protection against the B. ovis challenge. Although ocular instillation of BLSOmp31/CpG-ODN/Coa-ASC16 showed a similar degree of protection compared to the parenteral route (3.66 and 3.60 logs of protection, respectively), it induced lower levels in serum of specific IgG (with mixed IgG1/IgG2a) and IgA antibodies and, less IFN-? and IL-4 than the subcutaneous route. No antibodies were detected in vaginal lavages or saliva. Fecal antigen-specific IgA was slightly higher in mice immunized with BLSOmp31/CpG-ODN/Coa-ASC16 subcutaneously compared with the ocular route. These results indicate that BLSOmp31/CpG-ODN/Coa-ASC16 was a safe and effective vaccine against B. ovis in mice.
    Original languageEnglish
    Pages (from-to)217-227
    Number of pages11
    JournalResearch in Veterinary Science
    Volume135
    DOIs
    Publication statusPublished - 2021

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Keywords

    • BLSOmp31
    • CpG-ODN
    • Coa-ASC16
    • Experimental vaccine
    • Immune response
    • Brucella ovis
    • Protection
    • Murine model

    Cite this